This Article Full Text Full Text (PDF) Other Versions of this Article: IAI.01932-06v1 75/6/3006    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rhodes, S. G. Articles by Vordermeier, H. M. Search for Related Content PubMed PubMed Citation Articles by Rhodes, S. G. Articles by Vordermeier, H. M.

 Previous Article  |  Next Article 

Infection and Immunity, June 2007, p. 3006-3013, Vol. 75, No. 6
0019-9567/07/$08.00+0     doi:10.1128/IAI.01932-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Is Interleukin-43 Splice Variant Expression in Bovine Tuberculosis a Marker of Protective Immunity?

Veterinary Laboratories Agency, Surrey KT15 3NB, United Kingdom,¹ Institute of Veterinary Pathology, University of Berne, Berne CH-3001, Switzerland²

Received 7 December 2006/ Returned for modification 19 January 2007/ Accepted 14 March 2007

Splice variants of the interleukin-4 (IL-4) cytokine gene have been described for humans, mice, and cattle. IL-4 splice variants have been shown to inhibit IL-4-mediated cellular responses and thus act as IL-4 antagonists. Recent work has highlighted the possibility of a correlation between IL-4 splice variants and protection against clinical tuberculosis. In this study we investigated the potential role of IL-4 splice variants IL-42 and IL-43 in cattle with bovine tuberculosis, using quantitative real-time reverse transcription-PCR. For this analysis we used naturally exposed tuberculin skin test-positive field reactor cattle, uninfected control cattle, and cattle from two experimental models of protective immunity against Mycobacterium bovis: (i) vaccination with M. bovis BCG and challenge with virulent M. bovis and (ii) infection with M. bovis and treatment with isoniazid (INH) prior to rechallenge. The cytokine levels of field reactor cattle were compared to the levels of uninfected controls, while in kinetic studies of BCG vaccination and INH treatment we compared pre-experimental values with sequential samples for each individual animal. The data revealed a significant increase in IL-43 mRNA expression in field reactor cattle, which had no visible pathology compared to cattle with gross pathology typical of bovine tuberculosis. Increased IL-43 expression in both cattle models of protective immunity (BCG vaccination and INH treatment) was transient over time, reaching significance in the INH treatment model. Our results support the hypothesis that IL-43 is involved in protective immunity against M. bovis infection in cattle and are in accordance with clinical studies that have suggested a role for IL-4 splice variants in protective immunity in tuberculosis.

Published ahead of print on 26 March 2007.

Editor: J. L. Flynn